Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
215.36
-0.76 (-0.35%)
Aug 7, 2026, 11:53 AM EDT - Market open
Alnylam Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 28,817 | 52,639 | 30,424 | 24,078 | 29,451 | 20,380 | |
Market Cap Growth | -47.60% | 73.02% | 26.36% | -18.24% | 44.51% | 34.68% |
Enterprise Value | 28,598 | 51,009 | 29,026 | 22,944 | 28,579 | 18,942 |
Last Close Price | 215.36 | 397.65 | 235.31 | 191.41 | 237.65 | 169.58 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 38.46 | 170.67 | - | - | - | - |
Forward PE | 25.16 | 60.03 | - | - | - | - |
PS Ratio | 6.02 | 14.17 | 13.53 | 13.17 | 28.39 | 24.14 |
PB Ratio | 21.34 | 66.70 | 453.50 | -109.13 | -186.13 | 34.65 |
P/TBV Ratio | 21.87 | 67.86 | 447.73 | - | - | 34.15 |
P/FCF Ratio | 35.27 | 113.11 | - | 574.04 | - | - |
P/OCF Ratio | 31.72 | 100.44 | - | 231.18 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.95 | 13.73 | 12.91 | 12.55 | 27.55 | 22.44 |
EV/EBITDA Ratio | 27.12 | 91.54 | - | - | - | - |
EV/EBIT Ratio | 28.60 | 101.70 | - | - | - | - |
EV/FCF Ratio | 34.88 | 109.61 | - | 547.01 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.90 | 1.56 | 18.69 | -5.73 | -8.08 | 1.63 |
Debt / EBITDA Ratio | 1.20 | 2.29 | - | - | - | - |
Debt / FCF Ratio | 1.60 | 2.75 | - | 31.12 | - | - |
Net Debt / Equity Ratio | -1.51 | -2.07 | -20.84 | 5.14 | 5.51 | -2.44 |
Net Debt / EBITDA Ratio | -1.93 | -2.92 | 11.63 | 4.97 | 1.18 | 2.17 |
Net Debt / FCF Ratio | -2.57 | -3.50 | 32.84 | -27.03 | 1.42 | 2.00 |
Asset Turnover | 0.91 | 0.81 | 0.56 | 0.50 | 0.29 | 0.24 |
Inventory Turnover | 10.87 | 8.46 | 3.86 | 2.85 | 1.57 | 1.73 |
Quick Ratio | 2.79 | 2.51 | 2.61 | 2.86 | 3.16 | 3.79 |
Current Ratio | 3.05 | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 |
Return on Equity (ROE) | 75.40% | 73.28% | 362.29% | 232.40% | -526.14% | -106.31% |
Return on Assets (ROA) | 19.20% | 10.58% | -3.23% | -7.77% | -21.92% | -20.12% |
Return on Invested Capital (ROIC) | - | - | -17.04% | -10.16% | -81.71% | - |
Return on Capital Employed (ROCE) | 26.50% | 15.31% | -5.98% | -10.01% | -27.42% | -24.57% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.68% | 0.59% | - | - | - | - |
FCF Yield | 2.84% | 0.88% | - | 0.17% | - | - |
Buyback Yield / Dilution | -7.12% | -5.51% | -2.20% | -2.64% | -2.73% | -3.01% |
Total Shareholder Return | -7.12% | -5.51% | -2.20% | -2.64% | -2.73% | -3.01% |